Recognizing Osteoporosis and Its Consequences in Quebec (ROCQ) Programme

Summary

The aim of the ROCQ programme is to improve the use of evidence based osteoporosis diagnostic and treatment strategies for women 50 years and over who have suffered a fragility fracture. This objective will be achieved by concentrating on a realistic evaluation of the present diagnosis and treatment rate of osteoporosis following a fragility fracture and comparing it to an optimal situation (care gap) and proposing interventions that promote new approaches to treating osteoporosis by health professionals as well as providing targeted interventions for the patient. The efficacy of these interventions will be evaluated using a randomized control design.

Conditions

• Osteoporosis

Interventions

BEHAVIORAL

Documentation

Participants will receive written educational material for themselves as well as the Guidelines document for their physician (same written material as in the Educational Video Group). They will be asked to revisit their physician and provide written documentation inviting him/her to consider a complementary investigation and an adequate treatment according to the 2002 Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada

BEHAVIORAL

Video

Participants will receive a 15-minute educational video on osteoporosis. They will also receive written educational material for themselves and a Guidelines document for their physician. They will be asked to revisit their physician and provide the written documentation inviting her/him to consider a complementary investigation and an adequate treatment according to the 2002 Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada. Should participants wish to obtain additional information on osteoporosis, they will be provided with a toll-free number (1-866-571-ROCQ) to contact

Sponsors & Collaborators

• Merck Frosst Canada Ltd.

  collaborator INDUSTRY

• Sanofi

  collaborator INDUSTRY

• Procter and Gamble

  collaborator INDUSTRY

• Amgen

  collaborator INDUSTRY

• Eli Lilly and Company

  collaborator INDUSTRY

• Novartis

  collaborator INDUSTRY

• CHU de Quebec-Universite Laval

  lead OTHER

Principal Investigators

• Jacques P Brown, MD · CHU de Quebec

Study Design

Allocation

RANDOMIZED

Purpose

OTHER

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

50 Years

Sex

FEMALE

Healthy Volunteers

No

Timeline & Regulatory

Start

2003-06-30

Primary Completion

2007-10-31

Completion

2025-12-31

Countries

• Canada

Study Locations